CHICAGO, Aug. 15, 2017 /PRNewswire/ -- J.A.R. Laboratories, a leader in transdermal drug delivery announced the results of a trial comparing Over-the-Counter (OTC) LidoPatch® (lidocaine 3.6%, menthol 1.25%), prescription (Rx) (lidocaine 5%) and placebo in patients who suffer from arthritis and back pain. With many new OTC lidocaine patches on the market, LidoPatch® is unique in its formulation and the only OTC patch proven as effective as Rx lidocaine patches. In addition, LidoPatch® was proven to significantly improve patients’ pain, mood, and ability to perform normal activities when compared to placebo.
Switching to OTCs from Rx’s can provide benefits to patients and payers alike. There is the potential for less cost to the patient and could reduce the number of visits to their doctor. Payers gain an advantage by switching to a lower cost product and less resource utilization by its members.
Back pain is the second most common reason for a physician’s visit in the USA and the second most common reason to miss work. Both only behind the common cold.
Arthritis is a progressive disease that becomes much more common with age. By age 60, half of all Americans have dealt with some form of arthritis. And the incidence only goes up as we age more.
The study can be found here and here.
J.A.R. Laboratories
www.lidopatch.com
support@lidopatch.com
(866) 284-2948
Related Files
lidocaine patch study.pdf
Related Images
image1.png
image2.jpg
Related Links
LidoPatch® website
Article online
View original content with multimedia:http://www.prnewswire.com/news-releases/new-study-results-show-over-the-counter-lidopatch-as-effective-as-prescription-lidocaine-patches-300504414.html
SOURCE J.A.R. Laboratories
